Compare Stocks

Date Range: 

 Fate TherapeuticsAcceleron PharmaHalozyme TherapeuticsDenali TherapeuticsVir Biotechnology
SymbolNASDAQ:FATENASDAQ:XLRNNASDAQ:HALONASDAQ:DNLINASDAQ:VIR
Price Information
Current Price$76.49$118.18$47.57$54.30$42.97
52 Week RangeBuyBuyBuyBuyHold
MarketRank™
Overall Score1.81.81.51.51.4
Analysis Score4.44.41.43.43.2
Community Score3.03.02.72.52.2
Dividend Score0.00.00.00.00.0
Ownership Score1.71.71.71.71.7
Earnings & Valuation Score0.00.01.90.00.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyHold
Consensus Price Target$110.47$148.21$43.27$75.86$66.00
% Upside from Price Target44.42% upside25.41% upside-9.03% downside39.70% upside53.60% upside
Trade Information
Market Cap$7.18 billion$7.17 billion$6.82 billion$6.58 billion$5.50 billion
Beta1.880.591.772-0.99
Average Volume1,032,967371,8171,307,541563,9871,574,376
Sales & Book Value
Annual Revenue$10.68 million$73.99 million$195.99 million$26.68 million$8.09 million
Price / Sales672.4596.9534.78246.62679.79
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$3.24 per share$8.47 per share$0.63 per share$4.11 per share$3.87 per share
Price / Book23.6113.9575.5113.2111.10
Profitability
Net Income$-98,150,000.00$-124,860,000.00$-72,240,000.00$-197,610,000.00$-174,680,000.00
EPS($1.44)($2.38)($0.50)($2.07)($5.76)
Trailing P/E RatioN/AN/A297.31N/AN/A
Forward P/E RatioN/AN/A31.09N/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-810.13%-157.84%10.78%-968.59%-339.61%
Return on Equity (ROE)-35.51%-31.62%24.29%-39.19%-47.11%
Return on Assets (ROA)-25.40%-28.11%4.08%-30.71%-39.44%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A3.98%N/AN/A
Current Ratio9.17%12.02%18.49%9.21%11.03%
Quick Ratio9.17%12.02%16.36%9.21%11.03%
Ownership Information
Institutional Ownership Percentage99.67%79.78%98.45%68.15%54.49%
Insider Ownership Percentage21.41%2.50%2.60%19.30%37.20%
Miscellaneous
Employees279312136291327
Shares Outstanding93.89 million60.70 million143.30 million121.18 million127.99 million
Next Earnings Date8/4/2021 (Estimated)8/5/2021 (Estimated)5/10/2021 (Confirmed)8/6/2021 (Estimated)8/10/2021 (Estimated)
OptionableOptionableOptionableOptionableOptionableOptionable
SourceHeadline
Vir Biotechnology Inc. (NASDAQ:VIR) Has Recovered 41.1% So Far, But Another 228.16% Gain Cannot Be Ruled OutVir Biotechnology Inc. (NASDAQ:VIR) Has Recovered 41.1% So Far, But Another 228.16% Gain Cannot Be Ruled Out
marketingsentinel.com - May 8 at 12:57 PM
Amid vir­tu­al tri­al craze, Sci­ence 37 earns uni­corn sta­tus and a trip to Nas­daq on the back of SPAC dealAmid vir­tu­al tri­al craze, Sci­ence 37 earns uni­corn sta­tus and a trip to Nas­daq on the back of SPAC deal
endpts.com - May 7 at 10:20 AM
EMA starts rolling review of sotrovimab (VIR-7831) for COVID-19EMA starts rolling review of sotrovimab (VIR-7831) for COVID-19
poandpo.com - May 7 at 10:20 AM
EU regulator begins real-time review of GSK-Vir COVID-19 antibody drugEU regulator begins real-time review of GSK-Vir COVID-19 antibody drug
news.yahoo.com - May 7 at 7:10 AM
GSK and Vir Biotechnology Announce the Start of the EMA Rolling Review of VIR-7831 ...GSK and Vir Biotechnology Announce the Start of the EMA Rolling Review of VIR-7831 ...
apnews.com - May 7 at 7:10 AM
GSK and Vir Biotechnology Announce the Start of the EMA Rolling Review of  VIR-7831 (sotrovimab) for the Early Treatment of COVID-19GSK and Vir Biotechnology Announce the Start of the EMA Rolling Review of VIR-7831 (sotrovimab) for the Early Treatment of COVID-19
finance.yahoo.com - May 7 at 7:10 AM
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Misses Revenue EstimatesVir Biotechnology, Inc. (VIR) Reports Q1 Loss, Misses Revenue Estimates
finance.yahoo.com - May 7 at 12:06 AM
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2021 Financial ResultsVir Biotechnology Provides Corporate Update and Reports First Quarter 2021 Financial Results
finance.yahoo.com - May 6 at 7:05 PM
Herbert Virgin Sells 1,375 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) StockHerbert Virgin Sells 1,375 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) Stock
americanbankingnews.com - May 5 at 8:16 PM
COVID-19 treatment clinical trial moves to next phaseCOVID-19 treatment clinical trial moves to next phase
simcoereformer.ca - May 5 at 4:45 PM
COVID-19 treatment clinical trial moves to next stageCOVID-19 treatment clinical trial moves to next stage
theobserver.ca - May 5 at 4:45 PM
Vir Biotechnology earnings: heres what to expectVir Biotechnology earnings: here's what to expect
markets.businessinsider.com - May 4 at 2:01 PM
Vir Biotechnology, Inc. (NASDAQ:VIR) Has Been Rising 78.27% Since The Beginning Of The Year. Troubles Ahead?Vir Biotechnology, Inc. (NASDAQ:VIR) Has Been Rising 78.27% Since The Beginning Of The Year. Troubles Ahead?
marketingsentinel.com - May 1 at 1:36 PM
Vir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Weeks ReleaseVir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
finance.yahoo.com - April 29 at 6:16 PM
Insider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells 7,900 Shares of StockInsider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells 7,900 Shares of Stock
americanbankingnews.com - April 28 at 7:52 PM
The Taste with Vir Sanghvi: The slow death of hopeThe Taste with Vir Sanghvi: The slow death of hope
hindustantimes.com - April 27 at 7:25 AM
Brii Biosciences, Vir Biotechnology & VBI Vaccines begin patient dosing in phase 2 trial of BRII-835 in combo with BRII-179 to treat hepatitis BBrii Biosciences, Vir Biotechnology & VBI Vaccines begin patient dosing in phase 2 trial of BRII-835 in combo with BRII-179 to treat hepatitis B
pharmabiz.com - April 23 at 8:20 AM
Vir Biotechnology (NASDAQ:VIR) Downgraded by Zacks Investment ResearchVir Biotechnology (NASDAQ:VIR) Downgraded by Zacks Investment Research
marketbeat.com - April 23 at 5:59 AM
Vir Biotechnology to Provide Corporate Update and Report First Quarter 2021 Financial Results on May 6, 2021Vir Biotechnology to Provide Corporate Update and Report First Quarter 2021 Financial Results on May 6, 2021
finance.yahoo.com - April 22 at 7:30 PM
Brii Biosciences and Vir Biotechnology, Inc. and VBI Vaccines Inc.Brii Biosciences and Vir Biotechnology, Inc. and VBI Vaccines Inc.
businesswireindia.com - April 22 at 9:29 AM
Sack the guys who screwed up!Sack the guys who screwed up!
rediff.com - April 21 at 9:02 AM
Whats in the Cards for Eli Lilly (LLY) This Earnings Season?What's in the Cards for Eli Lilly (LLY) This Earnings Season?
finance.yahoo.com - April 21 at 8:11 AM
Brii Biosciences, Vir Biotechnology and VBI Vaccines Announce Initiation of  Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601)  for the Treatment of Hepatitis BBrii Biosciences, Vir Biotechnology and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
finance.yahoo.com - April 21 at 8:11 AM
Insider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells 2,340 Shares of StockInsider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells 2,340 Shares of Stock
americanbankingnews.com - April 20 at 7:42 PM
The Need for Comprehensive Diagnostics Remains as Cases Spike Once MoreThe Need for Comprehensive Diagnostics Remains as Cases Spike Once More
prnewswire.co.uk - April 20 at 9:52 AM
First patient dosed in latest stage of AGILE COVID-19 drug trialFirst patient dosed in latest stage of AGILE COVID-19 drug trial
miragenews.com - April 20 at 9:08 AM
DateCompanyBrokerageAction
5/7/2021Fate TherapeuticsWedbushUpgrade
4/26/2021Fate TherapeuticsJefferies Financial GroupInitiated Coverage
3/18/2021Fate TherapeuticsSVB LeerinkBoost Price Target
3/10/2021Fate TherapeuticsWells Fargo & CompanyBoost Price Target
3/3/2021Fate TherapeuticsMizuhoBoost Price Target
3/3/2021Fate TherapeuticsCantor FitzgeraldBoost Price Target
2/26/2021Fate TherapeuticsTruistBoost Price Target
2/26/2021Fate TherapeuticsBank of AmericaInitiated Coverage
2/25/2021Fate TherapeuticsRoth CapitalBoost Price Target
2/17/2021Fate TherapeuticsPiper SandlerBoost Price Target
2/11/2021Fate TherapeuticsCitigroupDowngrade
1/27/2021Fate TherapeuticsHC WainwrightReiterated Rating
1/25/2021Fate TherapeuticsBMO Capital MarketsBoost Price Target
1/19/2021Fate TherapeuticsOppenheimerReiterated Rating
1/15/2021Fate TherapeuticsBarclaysBoost Price Target
12/21/2020Fate TherapeuticsStifel NicolausBoost Price Target
3/29/2021Acceleron PharmaThe Goldman Sachs GroupReiterated Rating
3/17/2021Acceleron PharmaWolfe ResearchInitiated Coverage
3/4/2021Acceleron PharmaMorgan StanleyBoost Price Target
1/29/2021Acceleron PharmaJPMorgan Chase & Co.Boost Price Target
1/19/2021Acceleron PharmaRaymond JamesBoost Price Target
1/21/2021Halozyme TherapeuticsBenchmarkBoost Price Target
12/17/2020Halozyme TherapeuticsBerenberg BankInitiated Coverage
12/11/2020Halozyme TherapeuticsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target
12/11/2020Halozyme TherapeuticsSmith Barney CitigroupBoost Price Target
5/19/2020Halozyme TherapeuticsCanaccord GenuityReiterated Rating
5/12/2020Halozyme TherapeuticsJMP SecuritiesBoost Price Target
10/16/2020Denali TherapeuticsBTIG ResearchDowngrade
5/13/2020Denali TherapeuticsNomuraReiterated Rating
3/13/2020Denali TherapeuticsEvercore ISIUpgrade
3/9/2020Denali TherapeuticsNomura SecuritiesReiterated Rating
4/16/2021Vir BiotechnologyNeedham & Company LLCReiterated Rating
12/25/2020Vir BiotechnologyRobert W. BairdReiterated Rating
(Data available from 5/9/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.